Name of product: VIAGRA CONNECT^® 50 mg Film-coated Tablets

Active ingredient: Sildenafil

Product licence number: PL 46302/0325 

Name and address of the product licence holder: Viatris Products Limited, Station Close, Potters Bar, EN6 1TL, United Kingdom. 
Supply classification: P
Indications: For erectile dysfunction (ED) in adult men. 
Side Effects: Adverse reactions from post-marketing surveillance has been gathered covering an estimated period >10 years. Very Common (≥ 1/10): Headache. Common (≥ 1/100 and 
<1/10): Dizziness, Visual colour distortions (Chloropsia, Chromatopsia, Cyanopsia, Erythropsia and Xanthopsia), Visual disturbance, Vision blurred, Flushing, Hot flush, Nasal congestion, Nausea, Dyspepsia. Uncommon (≥ 1/1,000 and <1/100): Rhinitis, Hypersensitivity; Somnolence; Hypoaesthesia, Lacrimation disorders (Dry eye, Lacrimal disorder and Lacrimation increased), Eye pain, Photophobia, Photopsia, Ocular hyperaemia, Visual brightness, Conjunctivitis, Vertigo, Tinnitus, Tachycardia, Palpitations, Hypertension, Hypotension, Epistaxis, Sinus congestion, Gastro Oesophagael reflux disease, Vomiting, Abdominal pain upper, Dry mouth, Rash, Myalgia, Pain in extremity, Haematuria, Chest pain, Fatigue, Feeling hot, Heart rate increased. Rare (≥ 1/10,000 and <1/1,000): Cerebrovascular accident, Transient ischaemic attack, Seizure, Seizure recurrence, Syncope, Non-arteritic anterior ischaemic optic neuropathy (NAION), Retinal vascular occlusion, Retinal haemorrhage, Arteriosclerotic retinopathy, Retinal disorder, Glaucoma, Visual field defect, Diplopia, Visual acuity reduced, Myopia, Asthenopia, Vitreous floaters, Iris disorder, Mydriasis, Halo vision, Eye oedema, Eye swelling, Eye disorder, Conjunctival hyperaemia, Eye irritation, Abnormal sensation in eye, Eyelid oedema, Scleral discoloration, Deafness, Sudden cardiac death, Myocardial infarction, Ventricular arrhythmia, Atrial fibrillation, Unstable angina, Throat tightness, Nasal oedema, Nasal dryness, Hypoaesthesia oral, Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN),Penile haemorrhage, Priapism, Haematospermia, Erection increased, Irritability. 
Precautions: All men with ED should be advised to consult their doctor within 6 months for a clinical review of underlying conditions and risk factors associated with ED. If symptoms of ED have not improved after taking Viagra connect on several consecutive occasions or if their ED worsens, patients should consult their doctor. In the event of an erection that persists longer than 4 hours, or you experience sudden vision changes, stop taking Viagra connect immediately and seek urgent medical advice. 
Patients should consult their doctor before taking Viagra connect if they have: Uncontrolled hypertension, moderate to severe valvular disease, left ventricular dysfunction, hypertrophic obstructive and other cardiomyopathies, significant arrhythmias, increased susceptibility to vasodilators include those with left ventricular outflow obstruction e.g. aortic stenosis, or those with the rare syndrome of multiple system atrophy manifesting as severely impaired autonomic control of blood pressure, conditions predisposing them to priapism (e.g. sickle cell anaemia, multiple myeloma, or leukaemia), history of bleeding disorders or active peptic ulceration, hepatic impairment, severe renal impairment (creatinine clearance <30 mL/min), concomitant use with CYP3A4 inhibitors like ketoconazole, erythromycin, or cimetidine) and administration of sildenafil to patients taking alpha-blocker therapy may lead to symptomatic hypotension. 
Patients with cardiovascular disease should be advised that sexual activity carries a cardiac risk and if they experience chest pain during sexual activity they should refrain from any further sexual activity and seek medical attention immediately. Viagra connect is not recommended for patients who experience chest pain or breathlessness after light or moderate activity. Caution should be exercised when sildenafil is initiated in patients treated with sacubitril/valsartan. Contra-indications: Women, Men without ED, Men under 18 years of age, Men for whom sexual activity may be inadvisable 
Co-administration with Nitric oxide donors (such as amyl nitrite) or nitrates in any form, Ritonavir, Guanylate cyclase stimulators, e.g. riociguat. Hypersensitivity to the active substance or to any of the excipients, severe cardiovascular disorders e.g. recent (6 months) acute myocardial infarction, stroke, unstable angina or severe cardiac failure, severe hepatic impairment, hypotension (blood pressure < 90/50 mmHg), known hereditary degenerative retinal disorders, e.g. retinitis pigmentosa, loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy, regardless if this episode was in connection with previous PDE5 inhibitor exposure, anatomical deformation of the penis (e.g. angulation, cavernosal fibrosis or Peyronie's disease). The film coating of Viagra connect contains lactose and should not be administered to men with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption. Viagra connect contains less than 1 mmol sodium (23 mg) per tablet. Patients on low sodium diets can be informed that this medicinal product is essentially ‘sodium-free’. 
Dosage and Method of use: Viagra connect recommended dose is 50 mg approximately one hour before sexual activity, on an empty stomach with or without water. The maximum dosing frequency is once per day.  

Trade Price (exc VAT) 2 pack £8.82, 4 pack £16.17 and 8 pack £28.39’. Date of revision: 08/2026. UK-VIAC-2026-00045 

The SmPC for this product, including adverse reactions, precautions, contra-indications, and method of use can be found at:  http://www.mhra.gov.uk/Safetyinformation/Medicinesinformation/SPCandPILs/index.htm and from Viatris Medical Information, Building 4, Trident Place, Hatfield Business Park, Mosquito Way, Hatfield, Hertfordshire, AL10 9UL, phone no. 01707 853000, Email: info.uk@viatris.com 

Job code: UK-VIAC-2026-00045. Date of prep: Aug 2026